Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: A Gynecologic Oncology Group Study

Gynecologic Oncology

Volumn 126, Issue 3, 2012, Pages 424-427

  Aghajanian, Carol ^a   Sill, Michael W ^b,c   Secord, Angeles Alvarez ^d   Powell, Matthew A ^e   Steinhoff, Margaret ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Buffalo Niagara Enterprise   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Carcinosarcoma; Chemotherapy; Iniparib; Uterine cancer

Indexed keywords

CARBOPLATIN; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LABORATORY TEST; LEUKOPENIA; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; UROGENITAL TRACT DISEASE; UTERINE CARCINOSARCOMA; UTERUS CARCINOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CARBOPLATIN; CARCINOSARCOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; UTERINE NEOPLASMS;

EID: 84864400878     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.05.024     Document Type: Article

References (25)

1. S.G. Silverberg, and R.J. Kurman Tumors of the uterine corpus and gestational trophoblastic disease Atlas of tumor pathology, third series, Fasc 3 1991 Armed Forces Institute of Pathology Washington, DC 166 177
2. W.G. McCluggage Malignant biphasic uterine tumors: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 55 2002 321 325 (Pubitemid 34494168)
3. R.E. Slayton, J.A. Blessing, P.J. DiSaia, and W.A. Christopherson Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study Cancer Treat Rep 71 1987 661 662 (Pubitemid 17090275)
4. G.A. Omura, F.J. Major, J.A. Blessing, T.V. Sedlacek, J.T. Thigpen, and W.T. Creasman A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas Cancer 52 1983 626 632 (Pubitemid 13025913)
5. J.T. Thigpen, J.A. Blessing, J.W. Orr Jr., and P. DiSaia Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study Cancer Treat Rep 70 1986 271 274 (Pubitemid 16166174)
6. G.P. Sutton, J.A. Blessing, N. Rosenshein, G. Photopulos, and P.J. DiSaia Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group Study) Am J Obstet Gynecol 161 1989 309 312 (Pubitemid 19212192)
7. J.P. Curtin, J.A. Blessing, J.T. Soper, and K. DeGeest Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group Study Gynecol Oncol 83 2001 268 270 (Pubitemid 33033064)
8. D.S. Miller, J.A. Blessing, J. Schilder, A. Munkarah, and Y.C. Lee Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study Gynecol Oncol 98 2005 217 221 (Pubitemid 41019108)
9. Iniparib Investigator brochure (IB) November 2011
10. V. Ossovskaya, I.C. Koo, E.P. Kaldjian, C. Alvares, and B.M. Sherman Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types Genes Cancer 1 2010 812 821
11. FIGO Committee on Gynecologic Oncology FIGO staging for uterine sarcomas Int J Gynaecol Obstet 104 2009 177 178
12. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216 (Pubitemid 30099779)
13. F.A. Tavassoli, and P. Devilee World health organization classification of tumours Pathology and genetics of tumors of breast and female genital organs 2003 IARC Press Lyon
14. A.H. Calvert, D.R. Newell, L.A. Gumbrell, S. O'Reilly, M. Burnell, and F.E. Boxall Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1989 1748 1756 (Pubitemid 19272848)
15. R. Jelliffe Letter: creatinine clearance: bedside estimate Ann Intern Med 79 1973 604 605
16. R. Simon Optimal 2-stage trial design for phase II trials Control Clin Trials 10 1989 1 10 (Pubitemid 19099520)
17. M.W. Sill Adapting rejection boundaries when the targeted accrual is not attained in 2-stage phase II clinical trials Technical Report 04-01, Department of Biostatistics, University at Buffalo 2004
18. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
19. G. Sutton, V.L. Brunetto, L. Kilgore, J.T. Soper, R. McGehee, and G. Olt A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study Gynecol Oncol 79 2000 147 153
20. H.D. Homesley, V. Filiaci, M. Markman, P. Bitterman, L. Eaton, and L.C. Kilgore Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 526 531 (Pubitemid 350002959)
21. M.A. Powell, V.L. Filiaci, P.G. Rose, R.S. Mannel, P. Hanjani, and K. DeGeest Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group Study J Clin Oncol 28 2010 2727 2731
22. R.A. Lacour, E. Eusher, and E.N. Atkinson A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma Int J Gynecol Cancer 21 2011 517 522
23. A.H. Wolfson, M.F. Brady, T. Rocereto, R.S. Mannel, Y.C. Lee, and R.J. Futoran A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus Gynecol Oncol 107 2007 177 185 (Pubitemid 47575740)
24. T.D. Penning, G.D. Zhu, V.B. Gandhi, J. Gong, X. Liu, and Y. Shi Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[®-2-methylpyrrolidin-2-Y1]-1h-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer J Med Chem 52 2009 514 523
25. K.A. Menear, C. Adcock, R. Boulter, X.L. Cockcroft, L. Copsey, and A. Cranston 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H- PTHTH alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1 J Med Chem 51 2008 6581 6591